Long term survival of patients with advanced ovarian cancer treated with intraperitoneal radioimmunotherapy
- 1 January 2000
- journal article
- research article
- Published by Elsevier in International Journal of Gynecologic Cancer
- Vol. 10 (s1) , 44-46
- https://doi.org/10.1046/j.1525-1438.2000.99510.x
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube, and peritoneum: a Gynecologic Oncology Group Study.Journal of Clinical Oncology, 1998
- Intraperitoneal Cisplatin plus Intravenous Cyclophosphamide versus Intravenous Cisplatin plus Intravenous Cyclophosphamide for Stage III Ovarian CancerNew England Journal of Medicine, 1996
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerNew England Journal of Medicine, 1996
- Pharmacokinetics and toxicity of an yttrium‐90‐citc‐dtpa‐hmfg1 radioimmunoconjugate for intraperitoneal radioimmunotherapy of ovarian cancerCancer, 1994
- Adjuvant therapy of ovarian cancer with radioactive monoclonal antibodyBritish Journal of Cancer, 1993
- Long-term survival in ovarian cancerEuropean Journal of Cancer and Clinical Oncology, 1991
- Intraperitoneal yttrium-90-labeled monoclonal antibody in ovarian cancer.Journal of Clinical Oncology, 1990
- Monoclonal antibodies for imaging and therapyBritish Journal of Cancer, 1989
- Antibody-guided irradiation of advanced ovarian cancer with intraperitoneally administered radiolabeled monoclonal antibodies.Journal of Clinical Oncology, 1987
- TARGETING OF IODINE-123-LABELLED TUMOUR-ASSOCIATED MONOCLONAL ANTIBODIES TO OVARIAN, BREAST, AND GASTROINTESTINAL TUMOURSThe Lancet, 1982